Cargando…

Plasma androgen receptor and serum chromogranin A in advanced prostate cancer

Recently, mixed forms between adenocarcinoma and neuroendocrine prostate cancer (NEPC) have emerged that are characterized by persistent androgen receptor (AR)-signalling and elevated chromogranin A (CgA) levels. The main aim of this study was to analyze castration-resistant prostate cancer (CRPC) p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Conteduca, Vincenza, Scarpi, Emanuela, Salvi, Samanta, Casadio, Valentina, Lolli, Cristian, Gurioli, Giorgia, Schepisi, Giuseppe, Wetterskog, Daniel, Farolfi, Alberto, Menna, Cecilia, De Lisi, Delia, Burgio, Salvatore Luca, Beltran, Himisha, Attard, Gerhardt, De Giorgi, Ugo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194135/ https://www.ncbi.nlm.nih.gov/pubmed/30337589 http://dx.doi.org/10.1038/s41598-018-33774-4

Ejemplares similares

Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer
por: Salvi, Samanta, et al.
Publicado: (2016)

Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer
por: Conteduca, V., et al.
Publicado: (2017)

Vitamin D status among long-term survivors of testicular cancer
por: Schepisi, Giuseppe, et al.
Publicado: (2016)

Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer
por: Conteduca, Vincenza, et al.
Publicado: (2018)

Plasma Androgen Receptor in Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

Melphalan as a Promising Treatment for BRCA-Related Ovarian Carcinoma
por: Conteduca, Vincenza, et al.
Publicado: (2021)

Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide
por: Conteduca, Vincenza, et al.
Publicado: (2022)

Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer
por: Conteduca, Vincenza, et al.
Publicado: (2020)

Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide
por: Gurioli, Giorgia, et al.
Publicado: (2020)

Combining liquid biopsy and functional imaging analysis in metastatic castration‐resistant prostate cancer helps predict treatment outcome
por: Conteduca, Vincenza, et al.
Publicado: (2021)

The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment
por: Brighi, Nicole, et al.
Publicado: (2019)

Cell-free DNA as a diagnostic marker for cancer: current insights
por: Salvi, Samanta, et al.
Publicado: (2016)

Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors
por: Schepisi, Giuseppe, et al.
Publicado: (2020)

Immunotherapy for Prostate Cancer: Where We Are Headed
por: Schepisi, Giuseppe, et al.
Publicado: (2017)

Psychosocial Issues in Long-Term Survivors of Testicular Cancer
por: Schepisi, Giuseppe, et al.
Publicado: (2019)

Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented test
por: González-Billalabeitia, Enrique, et al.
Publicado: (2018)

Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel
por: Gurioli, Giorgia, et al.
Publicado: (2022)

Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide
por: Del Re, M., et al.
Publicado: (2021)

Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer
por: Cursano, M. C., et al.
Publicado: (2022)

Genome-wide plasma DNA methylation features of metastatic prostate cancer
por: Wu, Anjui, et al.
Publicado: (2020)

Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone
por: Salvi, S, et al.
Publicado: (2015)

Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy
por: Schepisi, Giuseppe, et al.
Publicado: (2021)

Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy
por: Conteduca, Vincenza, et al.
Publicado: (2020)

Inflammatory Biomarkers as Predictors of Response to Immunotherapy in Urological Tumors
por: Schepisi, Giuseppe, et al.
Publicado: (2019)

Vitamin D Deficiency in Testicular Cancer Survivors: A Systematic Review
por: Schepisi, Giuseppe, et al.
Publicado: (2021)

Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients
por: Farolfi, Alberto, et al.
Publicado: (2023)

Identification of single nucleotide variants using position-specific error estimation in deep sequencing data
por: Kleftogiannis, Dimitrios, et al.
Publicado: (2019)

GSTP1 Methylation and Protein Expression in Prostate Cancer: Diagnostic Implications
por: Martignano, Filippo, et al.
Publicado: (2016)

Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging
por: Conteduca, Vincenza, et al.
Publicado: (2021)

Urine Cell-Free DNA Integrity Analysis for Early Detection of Prostate Cancer Patients
por: Salvi, Samanta, et al.
Publicado: (2015)

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
por: Conteduca, V., et al.
Publicado: (2017)

Epigenetics in prostate cancer: clinical implications
por: Conteduca, Vincenza, et al.
Publicado: (2021)

Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone
por: Lolli, Cristian, et al.
Publicado: (2016)

Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges
por: Trujillo, Blanca, et al.
Publicado: (2022)

Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone
por: De Giorgi, Ugo, et al.
Publicado: (2014)

Methylation pattern analysis in prostate cancer tissue: identification of biomarkers using an MS-MLPA approach
por: Gurioli, Giorgia, et al.
Publicado: (2016)

Prognostic Role of Systemic Inflammatory Indexes in Germ Cell Tumors Treated With High-Dose Chemotherapy
por: Cursano, Maria Concetta, et al.
Publicado: (2020)

A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer
por: Lolli, Cristian, et al.
Publicado: (2017)

Copy Number Analysis of 24 Oncogenes: MDM4 Identified as a Putative Marker for Low Recurrence Risk in Non Muscle Invasive Bladder Cancer
por: Salvi, Samanta, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_tf6jbol4cgr1llqds4akivgjdg